Shot Block: FDA Rejects Regeneron Pharmaceuticals (NASDAQ: REGN) Twice

Regeneron Pharmaceuticals faced a second rejection from the FDA for its lymphoma therapy, odronextamab, due to issues identified at a Catalent manufacturing facility.